aMAP评分及其联合肝脏硬度检测准确评估慢性乙型肝炎患者肝纤维化
研究纳入中国2个真实世界队列和2项多中心随机对照试验的2053例慢性乙型肝炎患者进行横断面分析,其中889例有治疗前后配对肝活检者进行纵向分析。aMAP评分诊断肝硬化和进展性纤维化的AUROC分别为0.788和0.757,与FIB-4和APRI相当或显著更高;aMAP联合LSM的阶梯式方案进一步提高诊断性能。纵向分析建立aMAP-LSM模型,治疗后诊断肝硬化和进展性纤维化的AUROC分别为0.839和0.840。
要点
- aMAP评分诊断肝硬化AUROC 0.788、进展性纤维化0.757,与FIB-4和APRI相当或显著更高。
- aMAP联合LSM阶梯式方案诊断肝硬化不确定区域29.7%、准确率82.3%,进展性纤维化不确定区域46.2%、准确率79.8%。
- aMAP-LSM模型对治疗后LSM显著下降者诊断肝硬化AUROC 0.828 vs 单用LSM 0.748,P<.001。
核心结论
- aMAP评分是诊断慢性乙型肝炎患者纤维化的有前景无创工具,aMAP-LSM模型可准确估计治疗后患者的纤维化分期。
研究设计与样本
- 研究纳入中国2个真实世界队列和2项多中心随机对照试验共2053例慢性乙型肝炎患者,其中2053例纳入横断面分析,889例有治疗前及治疗72或104周后配对肝活检者纳入纵向分析。
主要发现
- 横断面分析中aMAP诊断肝硬化和进展性纤维化的AUROC分别为0.788和0.757,与基于4因子的纤维化指数和天冬氨酸氨基转移酶-血小板比率指数相当或显著更高。
- aMAP联合LSM阶梯式方案诊断肝硬化和进展性纤维化的不确定区域最小,分别为29.7%和46.2%,准确率分别为82.3%和79.8%。
- 纵向分析建立aMAP-LSM模型,治疗后诊断肝硬化和进展性纤维化的AUROC分别为0.839和0.840。
- 对治疗后LSM显著下降者,aMAP-LSM模型诊断肝硬化AUROC 0.828 vs 单用LSM 0.748(P<.001),诊断进展性纤维化AUROC 0.825 vs 单用LSM 0.750(P<.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The changes in liver stiffness measurement (LSM) are unreliable to estimate regression of fibrosis during antiviral treatment for chronic hepatitis B (CHB) patients. The age-male-albumin-bilirubin-platelets score (aMAP), as an accurate hepatocellular carcinoma risk score, may reflect the liver fibrosis stage. Here, we aimed to evaluate the performance of aMAP for diagnosing liver fibrosis in CHB patients with or without treatment. METHODS: A total of 2053 patients from 2 real-world cohorts and 2 multicentric randomized controlled trials in China were enrolled, among which 2053 CHB patients were included in the cross-sectional analysis, and 889 CHB patients with paired liver biopsies before and after 72 or 104 weeks of treatment were included in the longitudinal analysis. RESULTS: In the cross-sectional analysis, the areas under the receiver operating characteristic curve of aMAP in diagnosing cirrhosis and advanced fibrosis were 0.788 and 0.757, which were comparable with or significantly higher than those of the fibrosis index based on 4 factors and the aspartate aminotransferase-platelet ratio. The stepwise approach using aMAP and LSM further improved performance in detecting cirrhosis and advanced fibrosis with the smallest uncertainty area (29.7% and 46.2%, respectively) and high accuracy (82.3% and 79.8%, respectively). In the longitudinal analysis, we established a novel model (aMAP-LSM model) by calculating aMAP and LSM results before and after treatment, which had satisfactory performance in diagnosing cirrhosis and advanced fibrosis after treatment (area under the receiver operating characteristic curve, 0.839 and 0.840, respectively), especially for those with a significant decrease in LSM after treatment (vs LSM alone, 0.828 vs 0.748; P < .001 [cirrhosis]; 0.825 vs 0.750; P < .001 [advanced fibrosis]). CONCLUSIONS: The aMAP score is a promising noninvasive tool for diagnosing fibrosis in CHB patients. The aMAP-LSM model could accurately estimate fibrosis stage for treated CHB patients.
引用
- Fan R, Li G, Yu N, et al. aMAP Score and Its Combination With Liver Stiffness Measurement Accurately Assess Liver Fibrosis in Chronic Hepatitis B Patients. Clin Gastroenterol Hepatol. 2023. PMID: 36933605. doi:10.1016/j.cgh.2023.03.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。